Design of a biomarker of DUX4 activity to evaluate losmapimod treatment effect in FSHD Phase 2 trials

被引：0
|
作者：
Ronco, L. [1 ]
Cadavid, D. [1 ]
Chang, A. [1 ]
Mellion, M. [1 ]
Rojas, A. [1 ]
Shen, N. [1 ]
Tawil, R. [2 ]
Tapscott, S. [3 ]
Wang, L. [3 ]
Wallace, O. [1 ]
机构：
[1] Fulcrum Therapeut, Cambridge, MA USA
[2] Univ Rochester, Med Center
[3] Univ Washington, Seattle, WA 98195 USA
来源：
NEUROMUSCULAR DISORDERS | 2019年 / 29卷
关键词：
D O I：
10.1016/j.nmd.2019.06.076
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.47
引用
收藏
页码：S54 / S55
页数：2
相关论文
共 50 条
  • [21] A Phase 2, randomized, placebo-controlled, 24-Week study of the efficacy and safety of losmapimod in treating subjects with FSHD: ReDUX4
    Mellion, M.
    Tawil, R.
    Ronco, L.
    Rahilly, A.
    Rojas, A.
    Odueyungbo, A.
    Wagner, K.
    Statland, J.
    Wang, L.
    Genge, A.
    Gibson, S.
    Goyal, N.
    Hamel, J.
    Johnson, N.
    Lochmuller, H.
    LoRusso, S.
    Pestronk, A.
    Sacconi, S.
    Shieh, P.
    Cadavid, D.
    NEUROMUSCULAR DISORDERS, 2020, 30 : S112 - S112
  • [22] Sporadic DUX4 expression in FSHD myocytes is associated with incomplete repression by the PRC2 complex and gain of H3K9 acetylation on the contracted D4Z4 allele
    Premi Haynes
    Karol Bomsztyk
    Daniel G. Miller
    Epigenetics & Chromatin, 11
  • [23] Sporadic DUX4 expression in FSHD myocytes is associated with incomplete repression by the PRC2 complex and gain of H3K9 acetylation on the contracted D4Z4 allele
    Haynes, Premi
    Bomsztyk, Karol
    Miller, Daniel G.
    EPIGENETICS & CHROMATIN, 2018, 11
  • [24] A phase 2, randomized, double-blind, placebo-controlled, 48-Week study of the efficacy and safety of losmapimod in subjects with FSHD: ReDUX4
    Tawil, R.
    Wagner, K.
    NEUROMUSCULAR DISORDERS, 2021, 31 : S48 - S49
  • [25] Annualized rates of change from a phase 2, randomized, double-blind, placebo-controlled, 48-week study of losmapimod in subjects with FSHD: ReDUX4
    Tawil, R.
    NEUROMUSCULAR DISORDERS, 2022, 32 : S105 - S105
  • [26] Annualized Rates of Change from A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 48-Week Study of Losmapimod in Subjects with FSHD: ReDUX4
    Tawil, Alrabi
    NEUROLOGY, 2023, 100 (17)
  • [27] Adaptive Informational Design of Confirmatory Phase III Trials With an Uncertain Biomarker Effect to Improve the Probability of Success
    Chen, Cong
    Li, Nicole
    Yue Shentu
    Pang, Lei
    Beckman, Robert A.
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2016, 8 (03): : 237 - 247
  • [28] Design of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, 24-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Subjects with Facioscapulohumeral Muscular Dystrophy (FSHD): ReDUX4
    Tawil, Alrabi
    Mellion, Michelle
    Ronco, Lucienne
    Raines, Shane
    Tracewell, William
    Rahilly, Alisa
    Rojas, Alejandro
    Hage, Michelle
    Wagner, Kathryn
    Statland, Jeffrey
    Wang, Leo
    Evangelista, Teresinha
    Genge, Angela
    Gibson, Summer
    Goyal, Namita
    Hamel, Johanna
    Hayward, Lawrence
    Johnson, Nicholas
    Kornblum, Cornelia
    Lochmuller, Hanns
    LoRusso, Samantha
    Diaz Manera, Jordi
    Vilchez Padilla, Juan
    Pestronk, Alan
    Sacconi, Sabrina
    Schoser, Benedikt
    Shieh, Perry
    Subramony, S.
    Cadavid, Diego
    NEUROLOGY, 2020, 94 (15)
  • [29] Inference on treatment effect modification by biomarker response in a three-phase sampling design
    Juraska, Michal
    Huang, Ying
    Gilbert, Peter B.
    BIOSTATISTICS, 2020, 21 (03) : 545 - 560
  • [30] Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease
    Wils, Pauline
    Jairath, Vipul
    Sands, Bruce E.
    Magro, Fernando
    Reinisch, Walter
    Rubin, David
    Danese, Silvio
    Baumann, Cedric
    Peyrin-Biroulet, Laurent
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2023, 11 (08) : 797 - 806
12345